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Abstract
The LIM and SH3 protein 1 (LASP1) is a focal adhesion protein. Its expression is increased
in many malignant tumors. However, little is known about the physiological role of the pro-
tein. In the present study, we investigated the expression and function of LASP1 in normal
skin, melanocytic nevi and malignant melanoma. In normal skin, a distinct LASP1 expres-
sion is visible only in the basal epidermal layer while in nevi LASP1 protein is detected in all
melanocytes. Melanoma exhibit no increase in LASP1 mRNA compared to normal skin. In
melanocytes, the protein is bound to dynamin and mainly localized at late melanosomes
along the edges and at the tips of the cell. Knockdown of LASP1 results in increased mela-
nin concentration in the cells. Collectively, we identified LASP1 as a hitherto unknown pro-
tein in melanocytes and as novel partner of dynamin in the physiological process of
membrane constriction and melanosome vesicle release.
Introduction
Melanocytes are specialized cells of neuroectodermal origin that produce melanosomes, i.e. vesi-
cles in which melanin pigment is synthesized to protect the DNA of epidermal cells against UV
light-induced damage. Melanosomes are mainly produced around the nucleus of melanocytes,
then transported along microtubules and actin filaments to the dendrite tips of the cells and subse-
quently shed from the plasma membrane to finally become internalized by keratinocytes [1, 2].
The mechanisms involved in melanosome maturation, transport and release are highly dependent
on molecular motors along with multi-protein assemblies and cytoskeletal rearrangements [3].
We previously identified the LIM and SH3 protein 1 (LASP1) to be strongly expressed in
epidermal basal cells [4]. LASP1 is a scaffolding protein involved in cell migration and prolifer-
ation and preferentially localized at focal contacts and along the membrane edges of the cell
[5]. LASP1 harbours an N-terminal LIM domain, followed by two actin-binding nebulin
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repeats, a linker domain and a C-terminal Src homology 3 (SH3) domain [6]. Various cytoskel-
eton proteins have been identified that bind to LASP1: F-actin [7], kelch-related protein [8],
zyxin [9], lipoma preferred partner [7], zona occludens protein 2 (ZO2) [10], dynamin [10],
VASP [7], CRKL [11] and CXCR2 [12], respectively.
Phosphorylation by protein kinases A and G at serine 146 reduces binding of LASP1 to F-
actin, increases cytosolic distribution and enables nuclear shuttling by binding to zona occlu-
dens protein 2 (ZO2) [10]. Phosphorylation at tyrosine 171 by Abl-kinase blocks LASP1 trans-
location to focal complexes [13].
LASP1 is overexpressed in a multitude of cancers. Several studies demonstrated that LASP1
expression and nuclear localization positively correlated with malignancy, tumor grade, and
metastatic lymph node status (for review see: [14]).
A previously reported physiological LASP1-depending process that resembles melanosome
release by melanocytes is the secretory HCl response in gastric parietal cells [15, 16]. Stimulation
of acid secretion involves the translocation of H+/K+-ATPase vesicles from the cell cortex to the
apical membrane of the parietal cell, followed by vesicle fusion with the plasma membrane.
We therefore studied LASP1 expression in skin tissue samples, in normal human epidermal
melanocytes (NHEMs) and in melanoma cell lines and identified LASP1 as a yet unknown pro-
tein in melanocytes and as novel partner of dynamin in the complex process of melanosome
vesicle release at the dendrite tips.
Materials and Methods
Tissue samples
112 archived formalin-fixed and paraffin-embedded (FFPE) tissue specimens (including 58
primary malignant melanomas, 20 independent melanoma metastases, 29 melanocytic nevi
and 5 normal skin samples) were obtained by surgical excision for either therapeutic or diag-
nostic purposes and had undergone routine histology at the Department of Dermatology, Uni-
versity Hospital Würzburg, Würzburg, Germany. The institutional review board of the
University Hospital Würzburg, Germany, specifically approved this study and waived the need
for written informed consent from the donors.
Immunohistochemistry
Immunohistochemistry of tissue samples was carried out on 4 consecutive sections as de-
scribed earlier [17]. Tissue sections were incubated overnight at 4°C with antibodies recogniz-
ing LASP1 (1:1000) [7] and MART1 (Dako, M7196, 1:200) diluted in PBS.
Immunostained sections were evaluated by two independent scientists to define the percent-
age of LASP1-positive cells and to determine nuclear and cytosolic immunoreactivity. Cytosol-
ic LASP1 expression was quantified in analogy to the scoring of the hormone receptor Immune
Reactive Score (IRS), ranging from 0–12 according to Remmele et al. and as described in detail
for LASP1 in breast cancer [4, 18]. For statistical discrimination, samples scored with cytosolic
LASP1-IRS<3 were classified as LASP1-negative and those with LASP1-IRS3 as LASP1-po-
sitive. Nuclear LASP1 positivity was scored by determining the percentage of positive nuclei re-
gardless of cytosolic LASP1 immunoreactivity. Samples were considered to be nuclear-positive
if 10% or more cells showed nuclear LASP1 staining.
Cell lines and culture conditions
Human primary melanoma cell lines LOXIMVI, M14, MDAMB435, SKMel5, SKMel2,
M19-Mel [19], UACC62, UACC257 [20] and the subcutaneous metastasis cell line MaMel2
LASP1 in Melanocytes
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[21] were cultured in DMEM supplemented with 10% fetal calf serum and penicillin/strepto-
mycin (100 Uml−1, Gibco, Darmstadt, Germany). Normal human epidermal melanocytes
(NHEMs) were purchased from PromoCell (Heidelberg, Germany) and cultured in HAM's
F10 medium supplemented with 20% fetal bovine serum, glutamine, ITS premix, 12-O-tetrade-
canoylphorbol-13-acetate, IBMX, and cholera toxin (Gibco).
Western blot (WB)
For Western blotting, cells were lysed in 2x Laemmli sample buffer (65.8 mM Tris-HCl, pH
6.8, 26.3% (w/v) glycerol, 2.1% SDS, 0.01% bromophenol blue). Equal amounts of protein, ac-
cording to cell count, were resolved by 10% SDS-PAGE. After blotting on a nitrocellulose
membrane (Schleicher und Schuell, Kassel, Germany) and blocking with 3% nonfat dry milk
(Biorad, Munich, Germany) in 10 mM Tris, pH 7.5, 100 mMNaCl, 0.1% (w/v) Tween 20, the
membrane was first incubated with a self-generated polyclonal rabbit antibody against LASP1
(diluted 1:1000) [4], a mouse monoclonal antibody against dynamin (diluted 1:200; Santa
Cruz, Heidelberg, Germany), or rabbit polyclonal antibodies against TRP1 (diluted 1:200;
Santa Cruz), tyrosinase (diluted 1:200, Santa Cruz) or β-actin (diluted 1:5000, Sigma-Aldrich,
Deisenhofen, Germany). Thereafter, membranes were incubated with horseradish peroxidase-
coupled goat anti-rabbit or anti-mouse IgG (diluted 1:5000; Biorad, Munich, Germany). Sig-
nals were subsequently visualized by ECL (Amersham Biosciences, Freiburg, Germany) and
quantified by densitometry using the ImageJ software (NIH, Bethesda, USA).
p53 status
Most of the melanoma cell lines used in this study belong to the well- characterized NCI-60
panel for which p53 mutation data are available http://p53.free.fr/Database/Cancer_cell_lines/
NCI_60_cell_lines.html. The remaining cell lines were analyzed by sequencing the p53 exons
5–8. Genomic DNA was extracted from the different melanoma cell lines and subjected to
semi-nested PCR using previously reported primers [22]. The amplicons were analyzed by
Sanger sequencing.
Microarray analysis
Publicly available gene expression data of n = 604 individual tissue samples were retrieved
from the Gene Expression Omnibus (GEO). All data were generated on Affymetrix HG-U133-
plus2.0 microarrays. Accession codes: n = 353 normal body atlas GSE3526 [23]; n = 166 mela-
noma GSE10282, GSE15605, and GSE35640; n = 85 normal skin GSE14905 and GSE13355.
Expression data were manually revised for their correct annotations and simultaneously nor-
malized by Robust Multi-array Average (RMA) [24] using custom brainarray (v18 ENTREZG)
CDF files yielding one optimized probe-set for each gene corresponding to the ENTREZ gene
ID as described elsewhere [25–27]. Statistical analyses were performed using Prism v5.0b
(GraphPad Software, Inc.). P values< 0.05 were considered statistically significant (two-tailed
student’s t-test with Welch’s correction).
Immunofluorescence
For immunofluorescence microscopy cells were grown until 70% confluence on glass cover-
slips. Cells were fixed in 4% (w/v) paraformaldehyde in PBS, permeabilized with 0.1% (w/v)
Triton X-100 in PBS, and then stained with affinity-purified rabbit polyclonal antibody against
LASP1 (diluted 1 μg/ml) [4] in combination with either mouse monoclonal antibodies against
dynamin (diluted 1:20, Santa Cruz) or tyrosinase (diluted 1:20, Santa Cruz), followed by
LASP1 in Melanocytes
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secondary Cy3-labeled anti-rabbit antibody and Cy5-labeled anti-mouse antibody (diluted
1:250, Dianova, Hamburg, Germany). Nuclei were visualized with DAPI (diluted 1:1000,
Sigma-Aldrich). Omnifocal analyses were done with a Biorevo BZ-9000 (Keyence, Neu-Isen-
burg, Germany). The obtained data were processed by using Photoshop (Adobe Systems, San
Jose, CA, USA).
Preparation of nuclear and cytosolic cell fractions
For preparation of cell fractions, cells were harvested and washed twice in PBS. Isolation of nu-
clei and cytosol was carried out using NE-PER nuclear and cytoplasmic extraction reagents
(Pierce, Bonn, Germany) following the manufacturer's instructions.
siRNA transfection
Transfection for LASP1 knockdown was performed using metafectene (Biontex Laboratories
GmbH, Martinsried, Germany) according to the manufacturer’s protocol for suspension cul-
ture. Briefly, suspended cells were used at a density of 1x105 cells/ml and incubated directly
with the pre-incubated mixture of 12 μl metafectene and 1.2 μM control siRNA (AllStar nega-
tive control, Qiagen, Hilden, Germany) or LASP1 siRNA (5´-AAG CAT GCT TCC ATT GCG
AGA -3`(bases 80–100). Cells were cultured at 37°C under 5% CO2 atmosphere for 72h.
Proliferation assay
Cell viability was determined by the CellTiter-Glo Luminescent Cell Viability Assay (Promega,
Mannheim, Germany) according to the manufacturer´s instructions. In brief, cells transfected
with either siRNA against LASP1 or nonsense siRNA were cultured for 72h. Cell proliferation
was expressed as percentage of control cells. Four independent experiments were performed,
each with 8 replicates. In addition, cells were counted with a Neubauer chamber. Successful de-
pletion of LASP1 was confirmed by Western blot.
Adhesion assay
Cells were seeded in 48-well plates (4x104 cells per well) and allowed to attach for 4h at 37°C
(50% adhesion for control cells). Non-adherent cells were removed by gentle washing with PBS
and wells were refilled with 100 μl medium. Cells were counted using the CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega) according to the manufacturer´s instruction. Wells
with non-washed-off cells served as 100% control. Six independent experiments, each with 5
replicates, were performed. Successful knockdown of LASP1 was confirmed by Western blot.
Migration assay
Cellular migration was assessed by a modified Boyden chamber assay (transwell 8 μM pore size,
Corning Star, Cambridge, MA, USA). Cells were serum-starved overnight, trypsinized, adjusted
for viability, counted, and re-suspended in serum-free medium at a density of 1.5x106 cells/ml.
Prior to the experiment, the lower surface of the filter membrane was coated with 100 μl fibro-
nectin solution (5 μg/ml; Sigma-Aldrich) for 15 min as a chemo-attractant while the inner filter
chambers were coated with 100 μl 10% FCS in DMEMmedium for 30 min. 500 μl DMEMme-
dium with 10% FCS was added to the lower chamber of each transwell. 100 μl cell suspensions
(1.5x105 cells) were placed into the upper filter chambers. Cells were incubated for 6h (37°C;
5% CO2) to allow migration. Non-migrated cells from the upper chamber were removed using
a cotton swab. Migrated cells at the lower surface of the membranes were stained in 200 μl 1%
(w/v) crystal violet in 2% ethanol for 30 sec and rinsed twice afterwards in distilled water.
LASP1 in Melanocytes
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Cell-associated crystal violet was extracted by incubating the membrane in 200 μl 10% acetic
acid for 20 min and measured at 595 nm absorbance using a plate reader (Molecular Devices,
Crawley, UK). Three independent experiments, each with 6 replicates, were performed.
Melanin assay
Cells were transfected and seeded at a density of 1x105 cells/ml in 6-well plates. 72h post trans-
fection, cells were harvested, washed in PBS and lysed in 1N NaOH in 10% DMSO. Cellular
melanin was dissolved by incubating the homogenate at 80°C for 2h and then centrifuged at
500xg for 5 min. Absorbance of the supernatant was measured at 405nm. Synthetic melanin
(Sigma) was used as standard, ranging from 0–80 μg/ml.
Melanosome isolation by sucrose density gradient
Melanosomes were purified by ultracentrifugation as described [28]. For our experiments we
reduced all quantities to 1/10 of the original protocol. Briefly, the cellular homogenate was lay-
ered on a discontinuous gradient of 1.0, 1.2, 1.4, 1.5, 1.6, 1.8, and 2.0 M sucrose (in 10 mM
Hepes, pH 7.0) and centrifuged at 100,000xg in a Beckman SW 55 Ti swinging-bucket rotor for
1h at 4°C. Melanosomes that localized at various layers of the gradient were recovered by pi-
pette and analyzed by Western blot.
Pulldown
MaMel2 cells (1x106 cells) were lysed in 500 μl hypotonic buffer (Complete Mini) for 30 min
at 4°C, followed by mechanic lysis with a 29 1/2 gauge needle. After centrifugation for 30 min
at 20,000xg, the supernatant was incubated for 2h with GST-LASP1 beads or control GST-
beads, washed three times with PBS and analysed by SDS-PAGE and Western Blot for bound
proteins.
Statistics
Comparisons of patient characteristics between LASP1positive and LASP1negative protein expres-
sion were performed using Chi-Square test. Student’s t test was applied to determine effects of
siRNA knockdown on cell proliferation, adhesion and migration. A result was considered sig-
nificant at p0.05.
Results
LASP1 expression in normal skin and in nevi
We assessed LASP1 protein expression patterns by immunohistochemistry in normal skin and
melanocytic nevi with antibodies against LASP1 and MART1 in consecutive tissue sections.
LASP1 shows a positive immunostaining in the epidermal basal layer of normal skin (stra-
tum basale), composed of basal keratinocytes and pigment producing melanocytes (Fig 1A
upper left). The presence of interspersed melanocytes is confirmed by melanocyte-specific
MART1 staining in the consecutive section (Fig 1A upper right). Basal cells divide, differentiate
and migrate towards the surface. In these cells, the nuclei are very frequently LASP1-positive
(upper Fig 1B). Unlike to the stratum basale, the differentiating keratinocytes of the stratum
spinosum and the stratum granulosum are LASP1 negative (Fig 1A upper left). In the dermis,
histiocytes (yellow arrows) and blood vessels with vascular smooth muscle cells (red arrow)
also display LASP1-positivity (Fig 1A upper left). This has been observed earlier [29, 30].
Benign melanocytic nevi show high LASP1 protein expression in MART1-positive nevus
cells without nuclear LASP1 staining (lower Fig 1A and 1B).
LASP1 in Melanocytes
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LASP1 expression level in NHEM and melanoma cell lines
Next, we used Western blot (WB) to analyze the expression of LASP1 in cultured normal
human epidermal melanocytes (NHEMs) and different melanoma cell lines, which revealed
LASP1 expression in NHEMs as well as in all studied melanoma cell lines (Fig 2). For further
experiments, we chose MaMel2, a melanin-producing cell line derived from a subcutaneous
melanoma metastasis that showed higher LASP1 levels than NHEMs, and UACC257, a slightly
pigmented primary melanoma cell line with a LASP1 expression level similar to NHEMs.
Since LASP1 transcription is regulated in part by the tumor suppressor p53 [31] we validat-
ed and included the p53 status of the analyzed cell lines. However, no apparent correlation be-
tween LASP1 expression levels and p53 mutations was observed (Fig 2).
Knockdown of LASP1 is influencing migration and proliferation
To functionally assess the role of LASP1 in melanocytes and melanoma, we used NHEMs and
two melanoma cell lines, i.e. UACC257 and MaMel2. Cell lines were transfected with siRNA
against LASP1 or control siRNA. A profound reduction of ~75% of LASP1 protein expression
with maximum silencing after 72h is observed in the melanoma cells (Fig 3). Attempts to trans-
fect NHEM cells, either by transfection reagents (Metafectene, HiPerfect) or by Amaxa nucleo-
fector electroporation failed.
Since LASP1 has been shown to have a functional role in cell viability, motility and tumor
dissemination [13, 32–34], we also investigated cell migration, adhesion and proliferation in
melanoma cells before and after LASP1 silencing by using a modified Boyden chamber assay, a
fibronectin adhesion assay and an MTT viability test, respectively. Overall, only very minor
consequences could be measured. While adhesion was not affected by LASP1 knockdown in
MaMel2 and UACC257 cells (p>0.05), we observed a distinct reduction of the migratory
Fig 1. LASP1 expression in normal skin and nevi. (A) Representative immunohistochemical staining of consecutive sections from normal skin and from a
representative melanocytic nevus for LASP1 and the melanocytic antigen MART1 (magnification 20x; Scale bar = 100 μm). Stratum basale of normal skin
and nevus shows distinct LASP1-positivity. Histiocytes (yellow arrows) and a transverse cut blood vessel (red arrow) in the dermis display LASP1
expression. (B) Immunohistochemical LASP1 staining of normal skin and nevus at higher magnification (100x; Scale bar = 10 μm). Nuclear LASP1-positive
cells of the epidermal basal layer in normal skin are marked with arrows. Hematoxylin is used for counterstaining.
doi:10.1371/journal.pone.0129219.g001
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potential (~25%, p0.005) and a modest, but significant inhibition of proliferation (~10%,
p0.001) by MTT assay and by cell counting (Fig 3).
LASP1 binds to dynamin at the dendrite tips and contributes to melanin
release
As shown in Fig 1 LASP1 is highly expressed in melanocytic nevi, which are benign prolifera-
tions of melanin-producing melanocytes. Due to its domain structure, LASP1 can bind to sev-
eral proteins involved in melanosome vesicle trafficking, e.g. F-actin [35, 36] and dynamin [10,
37]. We speculated whether LASP1 might have a specific function in melanocytes and therefore
examined the melanin content of pigmented MaMel2 cells before and after LASP1 knockdown.
As shown in Fig 4A, LASP1 silencing induced a moderate, but significant elevation of the mela-
nin concentration in these cells (~10%, p = 0.03). Expression levels of tyrosinase and TRP1,
two major players in melanogenesis, were not affected by LASP1 knockdown.
Next we used immunofluorescence to examine a possible co-localization of LASP1 with
dynamin, a putative protein identified in melanosomes [37] and well-known for its involve-
ment in clathrin-coated vesicle trafficking [38] as well as with tyrosinase, a stage III and IV
melanosome marker.
Immunofluorescence imaging with NHEM (Fig 5A) and MaMel2 cells (Fig 5B) verified the
presence of dynamin and tyrosinase mainly at the Golgi apparatus around the nucleus and
along the cell membrane and tips of the cell. In NHEM cells, a clear punctual LASP1, dynamin
Fig 2. LASP1 expression in melanoma cell lines. Expression of LASP1 and β-actin in melanoma cell lines and in normal human epidermal melanocytes
(NHEMs) was determined byWestern blotting (10 μg protein per lane). Bar graphs represent mean and SEM integrated optical density of Western blot bands
from three individual experiments. The mutational status of the p53 oncogene is indicated for each cell line (wt wildtype; mt, mutant).
doi:10.1371/journal.pone.0129219.g002
LASP1 in Melanocytes
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Fig 3. LASP1 knockdown affects cell migration and proliferation. For analysis of proliferation, melanoma
cell lines transfected with LASP1 siRNA and control siRNA were seeded in 48-well-plates and incubated for
72h. Cells were counted with MTT viability assay and by Neubauer chamber. Bars, SEM; * Student´s t test,
p<0.05; versus control. For investigation of adhesion properties, LASP1-depleted cells were seeded in
48-well-plates and incubated for 4h. Non-adherent cells were washed-off, adherent cells were counted with
Promega Glo. Bars, SEM; n.s. p0.05, versus control. For migration analysis, LASP1-depleted cells were
seeded in modified Boyden chambers and incubated for 6h. Migrating cells were fixed with paraformaldehyde
and stained with crystal violet. The absorbance was measured. Bars, SEM; *** Student´s t test, p0.001;
versus control. A representative Western blot for LASP1 knockdown (~75%) in both cell lines is shown.
doi:10.1371/journal.pone.0129219.g003
LASP1 in Melanocytes
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and tyrosinase staining corresponding to few and discrete melanosomes is observed while in
highly pigmented MaMel2 cells increased melanocyte production is represented by a more dif-
fuse and bright staining of the cytosol mainly for dynamin and tyrosinase. Co-localization with
LASP1 is only observed at the cell membrane but not at the Golgi complex, suggesting a possi-
ble involvement of LASP1 in melanosome release. Control experiments without primary anti-
bodies revealed no staining with the secondary antibodies.
Next we asked whether the observed co-localization of LASP1 with dynamin is due to direct
or indirect physical interaction. To this end, we performed pull-down assays demonstrating
definite binding of dynamin to GST-LASP1 beads in MaMel2 and NHEM homogenates (Fig
4B). Binding to zyxin, a well-known LASP1 interacting partner [9], served as positive control
while no binding was observed with histone H2B (negative control). Similar results were ob-
tained with UACC257 cells (data not shown). Interestingly, all tested melanoma cell lines ex-
pressed dynamin to a higher extent than NHEM cells, independently of their pigmentation
status (Fig 4C).
Fig 4. Dynamin is a LASP1 binding partner. (A) Melanin concentration before and after LASP1 knockdown in MaMel2 cells. LASP1 knockdown efficiency
was controlled byWestern blot. Expression levels of tyrosinase and TRP1 are not affected. (B) Western blot analysis of dynamin, zyxin (positve control) and
histone H2B (negative control), pulled-down with GST control beads and GST-LASP1 fromMaMel2 and NHEM homogenate. (C) Western blot analysis of
dynamin and LASP1 expression in melanoma cell lines and normal human epidermal melanocytes (NHEM). β-Actin served as loading control.
doi:10.1371/journal.pone.0129219.g004
LASP1 in Melanocytes
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Fig 5. Immunofluorescence of LASP1, dynamin and tyrosinase in melanoma cells. NHEM (A) and MaMel2 (B) cells were fixed, permeabilized and
stained for LASP1 (red), dynamin or tyrosinase (both green) and nuclei (DAPI, blue). In merged cells, yellow visualizes a co-localisation of LASP1 with
dynamin or tyrosinase at the tips of the cell (indicated by white arrows).
doi:10.1371/journal.pone.0129219.g005
LASP1 in Melanocytes
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Identification of LASP1 and dynamin in melanosomes
Melanosomes mature within the melanocyte through four morphologically distinct stages [39]
that can be separated by sucrose density-gradient ultracentrifugation [28]. While 1.0 M and 1.2
M sucrose fractions contain the majority of stage I and stage II melanosomes, stages III and IV
are mainly detected in the 1.6 M and 1.8 M fractions. Immunoblot analysis of the fractions
demonstrated the highest protein concentration in the low density 1.0 M and 1.2 M sucrose
fractions (Fig 6A). High dynamin levels in this range reflect involvement of the protein in me-
lanosome budding from the Golgi complex. Tyrosinase was present in almost all parts of the
gradient while—in agreement with earlier publications [40]—TRP1 was more abundant in
fractions containing early-stage melanosomes (Fig 6A). The high LASP1 concentration in the
low density sucrose fractions does not represent LASP1 localization in early melanosomes but
reflects incomplete protein solubilization of this cytoskeleton-associated protein in the deter-
gent-free melanosome preparation buffer, as suggested by still high LASP1 levels in the “origi-
nal” after centrifugation (Fig 6A). The data is further supported by our immunofluorescence
images, showing no LASP1 co-localization with tyrosinase and dynamin along the Golgi appa-
ratus around the nucleus (Fig 5).
In contrast, however, LASP1, following a gradual decrease along the gradient, increased
again in the 1.8 M sucrose fraction, indicating discrete presence in stage IV melanosomes
(Fig 6A). Dynamin, tyrosinase and TRP1 also localized to this fraction and in two out of four
experiments, even dark melanosomes were visible in the 1.8 M sucrose fraction (Fig 6B).
In line with these results, co-localization of the LASP1-dynamin complex with melano-
somes at the tips of melanocyte dendrites is visible in Fig 6C. Furthermore, co-localization of
LASP1 and tyrosinase (Fig 7) perfectly matches with the peripheral melanosomes, visible as
dark spots in the bright-field illumination.
LASP1 expression decreases in melanocytic cells during tumor
progression
Cutaneous melanoma is a highly malignant neoplasm originating from melanocytes of the skin
and bears a high risk for metastatic spread. As LASP1 is overexpressed in several cancer entities
[14] it was tempting to speculate that the protein might also be involved in the development
and progression of melanoma.
We therefore assessed the LASP1 protein expression pattern by immunohistochemistry in
specimens from 29 melanocytic nevi, 58 malignant melanoma samples and 20 melanoma me-
tastases. Representative samples for the observed LASP1 immunoreactivity are shown in
Fig 8A. For semi-quantitative assessment, the percentage of LASP1-positive cells and staining
intensity were combined in the Immune Reactive Score (IRS), ranging from 0–12 [4, 18]. For
normal skin the IRS turned out to be 1 with LASP1-positivity in the basal epidermal cell layer
(Figs 1A, 1B and 8A) This is reflected by a moderate but significant (p = 0.0001) higher LASP1
mRNA level in normal skin as compared to a normal body atlas retrieved from the GEO
(Fig 8B).
For statistical evaluation of tumor samples a LASP1-IRS3 was classified as LASP1-posi-
tive. Based on this definition 62.0% of the benign nevi, 13.8% of the primary melanoma and
4.7% of the melanoma metastases were scored LASP1-positive (Table 1). Notably, these results,
demonstrating loss of LASP1 expression in the course of melanoma progression, are all based
on the presence of LASP1 in the cytoplasm since nuclear LASP1 staining, which is characteris-
tic for many aggressive LASP1-positive tumors (breast, prostate and liver carcinoma, medullo-
blastoma [4, 32, 41, 42]) was not observed in any of the melanocytic tumor samples (Table 1).
LASP1 in Melanocytes
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The observed low levels of LASP1 expression in melanoma and metastases are confirmed by
microarray data set analysis, revealing no increase in LASP1 mRNA expression in melanoma
when compared to normal skin (Fig 8B).
Fig 6. Co-localization of LASP1 and dynamin in melanosomes. (A) MaMel2 cells were prepared as described in “Materials and Methods” and loaded on a
sucrose density-gradient. Equal fraction volumes were subjected to SDS/PAGE and immunoblotted for LASP1, TRP1, tyrosinase and dynamin. “Original
before” indicates the loading sample in 0.25 M sucrose before centrifugation. “Original after” indicates the loading sample fraction after centrifugation. The
protein concentrations of the fractions and the corresponding melanosome stages are stated. (B) Sucrose density gradient tube with concentrated
melanosomes (indicated by black arrows) in the 1.8 M sucrose gradient fraction. (C) LASP1 (red) and dynamin (green) immunofluorescence at the dendrite
tip of a MaMel2 cell. Co-localization of the merged LASP1-dynamin complex (yellow) with melanosomes (black arrows) in the bright-field image at the
dendrite tip of the MaMel2 cell.
doi:10.1371/journal.pone.0129219.g006
LASP1 in Melanocytes
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To further examine a possible role of LASP1 in melanoma, we correlated LASP1 expression
levels with clinicopathological parameters of the patients (Table 2). There was no obvious cor-
relation between LASP1 expression and age, gender, tumor depth (AJCC guidelines) or meta-
static spread. For cancer-related death (CRD), a p-value of 0.05 is calculated. 75% of the
LASP1-positive patients died (6 out of 8) compared to 38% of LASP1- negative patients (19 out
of 50), assuming a trend to negative outcome for patients with LASP1 expression in melanoma.
However, the overall number of deceased LASP1-positive individuals (n = 8) is too low for a
statistically robust conclusion on CRD.
LASP1 is not localized in the nucleus in melanoma cell lines
A predominant nuclear localization of LASP1 is observed in several cancer entities [32, 43] and
was reported to correlate with worse long-time survival in breast cancer [44]. To confirm the
cytoplasmic LASP1 localization observed by immunohistochemistry of melanocytic tumors
(Fig 1), WB analysis of cytosolic and nuclear fractions from MaMel2, UACC257, and NHEM
Fig 7. Immunofluorescence of LASP1 and tyrosinase in NHEM cells. Black and white image of a NHEM cell with highlighted blue nucleus and circled
enlarged dendrite tip (upper panel). LASP1 (red) and tyrosinase (green) immunofluorescence at the dendrite tip of the NHEM cell (middle panels). Co-
localization of the merged LASP1-tyrosinase complex (white arrows) with pointed melanosomes (black arrows) in the bright-field image at the dendrite tip of
the NHEM cell (lower panels).
doi:10.1371/journal.pone.0129219.g007
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in comparison to MDAMB231 breast cancer cells was performed. Indeed, LASP1 and
pLASP1-S146 are exclusively detected in the cytosolic fraction of the melanoma cell lines and
NHEMs, while in breast cancer cells a distinct nuclear LASP1 signal is seen (Fig 9A).
LASP1 is known to shuttle between the cytosol and the nucleus in a phosphorylation-depen-
dent manner that requires binding of the protein to ZO2 [10]. We therefore analyzed i) the ex-
pression of potentially involved shuttle proteins in melanoma cells and ii) potential nuclear
translocation of LASP1 after forskolin-triggered protein kinase A (PKA) activation. As seen in Fig
9A, phosphorylation of LASP1 at Ser-146 by PKA is not inducing any translocation of the protein
to the nucleus of the melanocytic cells as it is observed for the breast cancer cell line MDAMB231,
which served as control. The nuclear absence of LASP1 in melanocytic cells may be explained by a
lack of expression of the essential shuttle partner ZO2 inMaMel2, SKMel5 and NHEM cells, how-
ever, in UACC257 LASP1 stays in the cytoplasm although ZO2 is present (Fig 9B).
Discussion
LASP1 was identified as a novel protein expressed by melanocytes and keratinocytes of the
basal epidermal layer in healthy skin. Moreover, LASP1 is expressed in melanocytic nevi while
Fig 8. LASP1 expression in normal skin, melanocytic nevi, melanoma andmetastases. (A) Representative immunohistochemical stainings of normal
skin, melanocytic nevus, melanoma, and metastasis tissue samples for LASP1. Hematoxylin counterstaining; magnification 20x; Scale bars = 100 μm). (B)
Gene expression patterns of LASP1 in skin tumor tissues: normal body atlas GSE3526; melanoma GSE10282, GSE15605, and GSE35640; normal skin
GSE14905 and GSE13355. The number of samples is given in parentheses. p values < 0.05 were considered statistically significant (two-tailed student’s t-
test with Welch’s correction).
doi:10.1371/journal.pone.0129219.g008
Table 1. LASP1 expression in samples of melanocytic nevi, primarymelanomas andmelanoma
metastases.
LASP1 positive cells (IRS3) LASP1 positive nuclei (10%)
Nevi (n = 29) 18 (62.0%) 0 (100%)
Melanoma (n = 58) 8 (13.8%) 0 (100%)
Metastasis (n = 20) 1 (4.7%) 0 (100%)
doi:10.1371/journal.pone.0129219.t001
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in primary melanoma and in metastases LASP1 levels are reduced. Keratinocytes in suprabasal
layers of the epidermis are LASP1-negative (Figs 1 and 8).
The LASP1-positive epidermal basal cells demonstrate nuclear LASP1 accumulation (Fig 1B).
In earlier studies, positive nuclear LASP1 staining was associated with aggressive, proliferative
cell growth and a transcriptional function or a role in cell cycle control for LASP1 in the nucleus
is discussed [32, 44]. In view of these data, the nuclear localization of LASP1 in this highly prolif-
erative cell layer is explainable.
Up to this study, LASP1 has been depicted as a protein being significantly upregulated in
numerous tumor entities: colon [43], bladder [45], prostate [41] breast [4], liver [42], gastric
[46], renal [47], oral malignant tumors [48] as well as medulloblastoma [32]. Several of these
studies demonstrate that LASP1 expression and nuclear localization are positively correlated
with malignancy, tumor grade and metastatic lymph node status [32, 41, 44]. Melanoma is the
first tumor tested so far, that is showing no LASP1 overexpression and obviously no involve-
ment in the development and progression of melanoma.
The primary function of melanocytes is the synthesis of melanin pigments in specific organ-
elles, termed melanosomes. In a first step, vesicles containing melanosomal proteins are bud
from the ER. The vesicles are moved forward to the Golgi apparatus around the nucleus. Then,
mature melanosomes are transported along microtubules and actin filaments towards the sur-
face of the melanocyte. During this transport the melanosomes pass through four stages: Non-
pigmented stage I vacuolar early endosomes; melanosomes stage II with fibrillar striations; pig-
mented melanosomes at stage III and IV with predominant expression of tyrosinase and TRP1.
Melanosomes at stage IV are released into the extracellular space and phagocytosed by kerati-
nocytes [1, 2, 39, 49].
In 2006, a proteomic characterization of melanosomes by tandem mass spectrometry listed
LASP1 and dynamin as putative proteins in these organelles, however, the presence of the pro-
teins was not validated [37]. Our sucrose gradient data now revealed co-localization of LASP1
with dynamin, tyrosinase and TRP1 in melanosomes at stage IV. Although dynamin plays a
pivotal role in vesicle trafficking from endosomes to the Golgi compartment, our
Table 2. Correlation of LASP1 expression to clinicopathological parameters in melanoma.
Parameter Melanoma LASP1 positive LASP1 negative P value
Number of patients 58 8 50
Sex 0.81
Male 34 3 29
Female 24 5 21
Age at primary diagnosis 0.13
60 22 1 21
>60 36 7 29
Lymph node metastases * 30 6 24 0.18
Distant metastases * 28 6 22 0.11
Tumor depth * (AJCC) 0.10
1–2 mm (T2) 26 3 23
2.1–4 mm (T3) 13 4 9
>4 mm (T4) 19 1 18
Cancer-related death * 25 6 19 0.05
* Tumor depth after AJCC guidelines.
** within 5 years of follow-up. Values of p were calculated by Chi-Square test; statistical significance is assumed when p<0.05.
doi:10.1371/journal.pone.0129219.t002
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immunofluorescence data clearly demonstrate the presence of the verified LASP1-dynamin
complex only along the melanocyte dendrite tips, assuming a role of this complex in melano-
some vesicle release.
According to the latest data on melanosome transfer [1], melanosomes are packed in vesi-
cles, budded off from melanocyte dendrites, released into the extracellular space, and then are
phagocytosed by keratinocytes [2]. The mechanisms of vesicle formation and scission, either
into the plasma membrane (endocytosis) or out of the Golgi apparatus, (secretion) are well
characterized [50] and the involvement of F-actin and dynamin in membrane fission has been
shown in many studies [51]. In view of these models, we are hypothesizing a possible participa-
tion of LASP1 in F-actin-dynamin mediated vesicle budding in melanocytes (Fig 10).
During exocytosis, dynamin forms helical polymers around the membrane neck of nascent
exocytic buds at the plasma membrane and by constriction of the helix, the membrane neck
Fig 9. Nuclear and cytosolic LASP1 distribution. (A) Western blot analysis of LASP1 and pLASP1-S146 in cytosolic (C) and nuclear (N) fractions of
MaMel2, UACC257, normal human epidermal melanocytes (NHEM) and breast cancer cell line MDAMB231 before and after forskolin stimulation.
Phosphorylation of LASP1 by PKA does not influence cytosolic LASP1 localization in melanoma cell lines and NHEM. Purity and loading of the fractions
were controlled byWestern blot for β-actin, the cytosolic marker GAPDH and the nuclear markers Lamin A/C and histone H2B. (B) Western blot analysis of
LASP1, ZO2 and PKA expression in MDA-MB 231 breast cancer cells compared to melanoma cell lines and NHEM. Loading was adjusted to similar β-
actin levels.
doi:10.1371/journal.pone.0129219.g009
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will break [52] resulting in shedding of melanosomes-containing vesicles into the extracellular
matrix [53]. This process involves several scaffolding proteins that connect the exocytotic ma-
chinery to the actin cytoskeleton of the cell, among themWASP, Arp2/3, CDC42, dynamin
and F-actin [50], the latter two known as LASP1 binding partners [35, 54]. Binding occurs be-
tween the N-terminal proline-rich repeat of dynamin with the SH3 domain of LASP1 [55] as
well as between F-actin and the actin-binding nebulin repeats in LASP1 [56]. Disruption of
this bridging complex by LASP1 knockdown is not crucial but leads to distinct reduction in
melanosome vesicle budding, concomitant with increased cellular melanin levels, as observed
in this study.
A comparable mechanism is discussed for the secretory HCl response in gastric parietal
cells. Herein, protein kinase A (PKA) phosphorylation of LASP1 regulates the trafficking/acti-
vation of the H+/K+-ATPase vesicles. In LASP1 knockout mice, histamine-stimulated PKA ac-
tivation induced a more robust acid secretory response [57]. The authors suggested a
phosphorylation-dependent alteration of LASP1 binding to F-actin and discussed ezrin as well
as dynamin as likely mediators, linking the vesicular trafficking machinery to the cytoskeleton.
However, none of these postulated interactions was verified at that time.
Fig 10. Proposedmodel for LASP1 involvement in actin-dynamin- mediatedmelanosome vesicle scission at melanocyte dendrite tips. In
anterograde melanosomal transport mature melanosomes move along microtubules by means of the motor protein kinesin and are transferred towards the
cell periphery. Once at the periphery, track switching frommicrotubules to actin filaments occurs, a process mediated by Rab27A and molecular motor
protein myosin Va (1). In this fashion microtubule, actin filaments and motor systems co-operate to promote melanosome transport and retention of the
organelle in peripheral dendrites. LASP1 and dynamin are present at the actin mesh at the plasmamembrane. LASP1 binds to actin and dynamin through its
nebulin repeat and SH3 domain, respectively. Dynamin exists as a dimer and binds to actin through the stalk region (2). WASP- and CDC42-mediated
activation of ARP2/3 lead to the branched polymerization of actin filaments towards the release site. Actin, together with other motor proteins, pushes the
plasmamembrane and enhances membrane invagination (3). As an adaptor/scaffolding protein, LASP1 recruits and positions dynamin at the tubular
membrane (4). Subsequent polymerization of dynamin around the membrane in a helical manner and GTP hydrolysis results in membrane constriction and
melanosome vesicle scission at dendrite tips (5 and 6).
doi:10.1371/journal.pone.0129219.g010
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In summary, we identified LASP1 as a hitherto unknown protein in melanocytes and as
novel partner of dynamin in the complex process of melanosome vesicle release.
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